Transaction · 0002031695-26-000011

McCulloch Kevin

McCulloch Kevin, SR, reported an open-market or private sale at Xeris Biopharma Holdings, Inc. involving 15000.000000 shares for an estimated $127308.00. Reported holdings after the transaction were 1639208.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SSR
XERSXeris Biopharma Holdings, Inc.
Filing timeSep 01
Trade dateSep 01, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$8.43
Pre-filing
1mo ago -4.2%1w ago +3.4%1d ago +0.1%
Returns since
7d +0.0%30d +0.0%90d +0.0%180d +0.0%1y +0.0%

XERS price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
XERS since 2026-09-01Filed 2 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0002031695-26-000011
Common Stock
Transaction date
Sep 01, 2026
Filed Sep 01, 2026, 10:21 PM · 0d delay
Shares
15.0k sh
$849 per share
Estimated value
-$12.7M
Computed from shares × price
Holdings after
1.63M sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Cluster Selling Direct Ownership 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

See Remarks

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025.

  2. F2

    The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.390 to $8.600, inclusive. The reporting person undertakes to provide to the Is…

  3. F3

    The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an…

Original filing · 0002031695-26-000011
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

XERS